...
首页> 外文期刊>Srpski Arhiv za Celokupno Lekarstvo >A rare case of isolated adrenal metastasis of invasive ductal breast carcinoma
【24h】

A rare case of isolated adrenal metastasis of invasive ductal breast carcinoma

机译:罕见的浸润性导管癌孤立性肾上腺转移病例

获取原文

摘要

Introduction. Isolated adrenal metastases of invasive ductal breast carcinoma are extremely rare. We report a case with isolated left adrenal metastases, verified three years after diagnosed breast carcinoma. Case Outline. A 58-year-old female patient with a right breast tumor, clinically staged as IIIA (T2N2M0) started neoadjuvant anthracycline chemotherapy after biopsy which revealed invasive ductal breast carcinoma. Immunohistochemical findings of tumor biopsy showed hormonal steroid receptors for estrogen and progesterone negative, and human epidermal growth factor receptor 2 (HER2) positive. After 4 cycles of chemotherapy and partial tumor regression the patient underwent radical mastectomy. Definite histopathological analysis confirmed the diagnosis of invasive ductal carcinoma. The patient continued treatment with adjuvant chemotherapy to cumulative dose of anthracyclines, postoperative radiotherapy and adjuvant trastuzumab for one year. Three years later abdominal computerized tomography showed tumor in the left adrenal gland as the only metastatic site. Left adrenalectomy was performed and histopathological finding confirmed breast cancer metastases. Postoperatively, the patient received 6 cycles of docetaxel with trastuzumab and continued trastuzumab until disease progression. One year after left adrenalectomy control abdominal computerized tomography showed a right adrenal tumor with retroperitoneal lymphadenopathy. Treatment with capecitabine was continued for one year, but eventually she developed brain metastasis causing lethal outcome. Conclusion. In order to better understand metastatic pathways of invasive ductal breast carcinoma, publications of individual patient cases diagnosed with rare metastatic sites should be encouraged. This might improve our understanding of metastatic behavior of breast cancer and stimulate further clinical research.
机译:介绍。浸润性导管癌的孤立性肾上腺转移极为罕见。我们报告了一例孤立的左肾上腺转移瘤,经确诊为乳腺癌三年后证实。案例大纲。一名58岁女性患有右乳腺肿瘤的女性患者,临床分期为IIIA(T2N2M0),在活检显示浸润性导管癌后开始新辅助蒽环类化疗。肿瘤活检的免疫组织化学结果显示雌激素和孕激素的激素类固醇受体阴性,人类表皮生长因子受体2(HER2)阳性。经过4个周期的化疗和部分肿瘤消退后,患者接受了根治性乳房切除术。明确的组织病理学分析证实了浸润性导管癌的诊断。该患者继续接受辅助化疗以达到蒽环类药物的累积剂量,术后放疗和曲妥珠单抗辅助治疗一年。三年后,腹部计算机断层扫描显示左肾上腺肿瘤是唯一的转移部位。进行了左肾上腺切除术并且组织病理学发现证实了乳腺癌转移。术后,患者接受6个周期的多西他赛联合曲妥珠单抗治疗,并继续使用曲妥珠单抗直至疾病进展。左肾上腺切除术控制一年后,腹部计算机断层扫描显示右肾上腺肿瘤伴腹膜后淋巴结肿大。卡培他滨治疗持续了一年,但最终她发生了脑转移并导致致命的后果。结论。为了更好地了解浸润性导管癌的转移途径,应鼓励发表诊断为罕见转移部位的个别患者案例。这可能会增进我们对乳腺癌转移行为的了解,并刺激进一步的临床研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号